Becton, Dickinson and Company
BDX Healthcare Medical - Instruments & Supplies NYSE
$168.65
$-1.29 (-0.76%)
Open: $168.26 | High: $169.42 | Low: $164.47 | Prev Close: $169.94
Market Cap: $61.10B
Volume: 1.5M | Avg: 2.8M
Last updated: March 06, 2026 at 08:00 PMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 502
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 27.60 |
| P/B Ratio | 1.90 |
| P/S Ratio | 2.79 |
| EPS | $6.11 |
| Beta | 0.31 |
| Shares Outstanding | 362.30M |
| 52-Week High | $187.35 |
| 52-Week Low | $127.59 |
| SMA 50 | $165.54 |
| SMA 200 | $150.23 |
| Dividend Yield | 1.94% |
| Annual Dividend | $3.28 |
| Next Earnings | April 30, 2026 12:00 PM ET |
Financial Ratios
| Gross Margin | 45.8% |
| Operating Margin | 12.4% |
| Net Margin | 8.0% |
| ROE | 6.9% |
| ROA | 3.2% |
| Debt/Equity | 0.77 |
| Current Ratio | 1.05 |
| Quick Ratio | 0.58 |
Balance Sheet
| Total Assets | $55.33B |
| Total Liabilities | $29.94B |
| Total Equity | $25.39B |
|
|
|
| Cash | $851.00M |
| Total Debt | $19.18B |
| Net Debt | $18.33B |
Income Statement
| Revenue | $21.84B |
| Gross Profit | $9.92B |
| Operating Income | $2.58B |
| Net Income | $1.68B |
|
|
|
| EBITDA | $4.96B |
| Revenue/Share | $76.90 |
Cash Flow
| Operating CF | $3.43B |
| CapEx | $760.00M |
| Free Cash Flow | $2.67B |
|
|
|
| Book Value/Share | $88.69 |
| Tangible Book/Share | $-36.35 |
| Equity/Share | $88.69 |
Technical Indicators
| RSI (14) | 32.37 Neutral |
| MACD |
-6.96
Signal: -5.96
|
| Volatility | 56.02% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | -4.74% |
| Sharpe Ratio | -0.18 Poor |
| Volatility (Ann.) | 30.75% Moderate |
| BDX (1Y) | -4.74% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -17.78% |
Sector Comparison (Healthcare)
| Metric | BDX | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 27.6 | 27.66 | 55% |
| P/B Ratio | 1.9 | -19.56 | 34% |
| ROE (%) | 6.93% | -9.42% | 26% |
| Net Margin (%) | 8.01% | 9.34% | 32% |
| Stock Score | 502 | 544.0 | 26% |
| 1Y Return (%) | -4.74 % | +8.40 % | 37% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BDX | $168.65 | $171.78 | $174.30 | $177.89 | $193.62 | $186.96 | 32.37 | -6.96 | 56.02% | 1544174 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the BDX stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| BDX | Why Is Becton Dickinson (BDX) Down 4.5% Since Last Earnings Report? | Neutral | zacks.com | Read More |
| BDX | Becton, Dickinson and Company (BDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript | Neutral | seekingalpha.com | Read More |
| BDX | 2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $1,000 | Neutral | fool.com | Read More |
| BDX | BDX Secures CE Mark for Revello Stent to Treat Iliac Artery Disease | Neutral | zacks.com | Read More |
| BDX | BD avanza en el tratamiento de la arteria ilíaca en toda la Unión Europea | Neutral | prnewswire.com | Read More |
Recent Insider Trading
No recent insider trading data available for BDX
Company Information
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
| CEO | Thomas E. Polen Jr. |
| Employees | 70000 |
| Country | US |
| IPO Date | 1973-02-21 |
| Exchange | NYSE |
| Website | https://www.bd.com |
| Sector | Healthcare |
| Industry | Medical - Instruments & Supplies |
Similar Stocks (Healthcare - Medical - Instruments & Supplies)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category